{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:12:16Z","timestamp":1790115136936,"version":"4.0.1"},"reference-count":32,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Emerging evidence points to heart failure as being a common first presentation of cardiovascular (CV) disease in type 2 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PURPOSE<\/jats:title>\n                  <jats:p>The purpose of this study was to determine whether hospitalization for heart failure (HHF) occurs more or less frequently than major adverse CV events (MACE) in people with type 2 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>DATA SOURCES<\/jats:title>\n                  <jats:p>Placebo arms of CV outcomes trials in type 2 diabetes were included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY SELECTION<\/jats:title>\n                  <jats:p>Sixteen CV outcomes trials were selected, including five dipeptidyl peptidase 4 inhibitor trials, seven glucagon-like peptide 1 receptor agonist trials, and four sodium\u2013glucose cotransporter 2 inhibitor trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>DATA EXTRACTION<\/jats:title>\n                  <jats:p>We extracted incidence rates of HHF, myocardial infarction (MI), stroke, and the composite outcomes of CV death or HHF and MACE (CV death, nonfatal MI, or nonfatal stroke).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>DATA SYNTHESIS<\/jats:title>\n                  <jats:p>In two trials enriched with people with chronic kidney disease, HHF was more common than both MI and stroke. Among the remaining 14 trials, HHF was less frequent than MI in 13 (93%), with this difference being significant in 8 (57%); however, HHF surpassed stroke in all but 1 study (93%; significant in 7 studies [50%]). Heterogeneity among trials was moderate\/high (I2 &amp;gt;50%) and partly explained by HHF\/MI correlating with age and previous MI history (P &amp;lt; 0.05). In seven trials that reported events stratified by presence\/absence of preexisting CV disease, ratios of HHF\/MI and HHF\/stroke were similar between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS<\/jats:title>\n                  <jats:p>Enrichment of trial populations with those at high risk of CV events limits generalizability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Although less frequent than MI, HHF is a common event in type 2 diabetes, both in those with and those without prior CV disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc20-0654","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:40:53Z","timestamp":1600735253000},"page":"2614-2623","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":14,"title":["Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials"],"prefix":"10.2337","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1315-3463","authenticated-orcid":false,"given":"Julian W.","family":"Sacre","sequence":"first","affiliation":[{"name":"Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-6096","authenticated-orcid":false,"given":"Dianna J.","family":"Magliano","sequence":"additional","affiliation":[{"name":"Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6187-2203","authenticated-orcid":false,"given":"Jonathan E.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"2022031223590498000_B1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031223590498000_B2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/heartjnl-2016-310342","article-title":"Diabetic cardiomyopathy","volume":"105","author":"Lee","year":"2019","journal-title":"Heart"},{"key":"2022031223590498000_B3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031223590498000_B4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/eurheartj\/ehm603","article-title":"Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition","volume":"29","author":"Zannad","year":"2008","journal-title":"Eur Heart J"},{"key":"2022031223590498000_B5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2213-8587(16)00049-8","article-title":"Heart failure event definitions in drug trials in patients with type 2 diabetes","volume":"4","author":"Sharma","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031223590498000_B6","unstructured":"U.S. Department of Health and Human Services\n          . Guidance for industry: Diabetes mellitus \u2014 evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet], 2008. Food and Drug Administration. Available from https:\/\/wayback.archive-it.org\/7993\/20190906002211\/https:\/\/www.fda.gov\/media\/71297\/download. Accessed 27 July 2020"},{"key":"2022031223590498000_B7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jacc.2018.01.047","article-title":"Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes","volume":"71","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022031223590498000_B8","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-017-0593-8","article-title":"A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus","volume":"16","author":"Gantz","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2022031223590498000_B12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2022031223590498000_B13","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B15","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B16","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B17","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2022031223590498000_B18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2022031223590498000_B19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B20","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B23","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIR.0000000000000156","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)","volume":"132","author":"Hicks","year":"2015","journal-title":"Circulation"},{"key":"2022031223590498000_B25","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2337\/diacare.26.8.2433","article-title":"Heart failure: the frequent, forgotten, and often fatal complication of diabetes","volume":"26","author":"Bell","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031223590498000_B26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/pds.1741","article-title":"Incidence rates of heart failure, stroke, and acute myocardial infarction among type 2 diabetic patients using insulin glargine and other insulin","volume":"18","author":"Juhaeri","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022031223590498000_B27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care editors\u2019 expert forum","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031223590498000_B28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"2022031223590498000_B30","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2337\/db13-0683","article-title":"Diabetes and the heart: is there objective evidence of a human diabetic cardiomyopathy","volume":"62","author":"Litwin","year":"2013","journal-title":"Diabetes"},{"key":"2022031223590498000_B31","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031223590498000_B32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc20-0654","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/10\/2614\/630170\/dc200654.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/10\/2614\/630170\/dc200654.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:58:14Z","timestamp":1647143894000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/43\/10\/2614\/35990\/Incidence-of-Hospitalization-for-Heart-Failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,11]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc20-0654","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,11]]}}}